![](https://equentis-web.s3.ap-south-1.amazonaws.com/static/1706695746928-r8arrow.png)
![](https://equentis-web.s3.ap-south-1.amazonaws.com/static/1706695746928-r8arrow.png)
![](https://equentis-web.s3.ap-south-1.amazonaws.com/static/1706695746928-r8arrow.png)
![](https://equentis-web.s3.ap-south-1.amazonaws.com/static/1706695746928-r8arrow.png)
Informed InvestoRR
A step by step guide to sharpen your investing skills
Pricing
Choose from our range of pricing packages
Get all the details on Emcure Pharmaceutical here!
Overview of Emcure Pharmaceutical Ltd IPO
IPO Date
3-Jul-2024 to 5-Jul-2024
Face Value
₹10
Price Band
₹960 to ₹1008
Lot Size
14 Shares Share
Issue Size
19,365,346 shares (aggregating up to ₹1,952.03 Cr)
Listing At
BSE,NSE
Basis of Allotment
8-Jun-2024
Initiation of Refunds
9-Jul-2024
Credit of Shares to Demat
9-Jul-2024
Listing Date
9-Jul-2024
Cut off time for UPI Mandate
5-Jul-2024
Objective of Emcure Pharmaceutical Ltd IPO
The net proceeds from the issuance of 7,936,507 Equity Shares (worth Rs 800 crs) will be utilized to repay debt (Rs 600 crs), and the rest of the funds (Rs 200 crs) have been kept for general corporate purposes.
About Emcure Pharmaceutical Ltd IPO
Emcure Pharma, established in 1981, is India's 13th-largest pharmaceutical company, engaged in developing, manufacturing, and globally marketing a diverse range of pharmaceutical products across 19 therapeutic areas. It caters to 70+ countries with a focus on India, Europe, and Canada. Region-wise revenue split (FY24): India - 48%, Europe - 21%, North America (predominantly Canada) - 14%, and Others (Emerging Markets) - 16%. Emcure holds a leadership position in gynecology and human immunodeficiency virus (HIV) (therapy areas in India in terms of Domestic Sales for MAT FY24).
Emcure Pharmaceutical Ltd IPO Financials
Particulars (in Cr) | FY24 | FY23 | FY22 |
---|---|---|---|
Total Revenue Annual | 6,658 | 5,986 | 5,855 |
Operating Expenses Annual | 5,429 | 4,805 | 4,525 |
Operating Profit Annual | 1,230 | 1,181 | 1,330 |
Depreciation | 312 | 260 | 245 |
Interest Annual | 237 | 214 | 176 |
Tax Annual | 6 | 10 | 8 |
Net Profit Annual | 528 | 562 | 703 |
Total Share Holder Funds | 2,952 | 2,501 | 1,988 |
Fixed Asset Annual | 1,949 | 1,605 | 1,470 |
Total Non Current Asset | 1,598 | 1,232 | 1,169 |
Total Current Asset | 4,260 | 3,836 | 3,424 |
Total Asset Annual | 7,806 | 6,673 | 6,063 |
Book Value Per Share | ₹ 163.22 | ₹ 138.30 | ₹ 109.90 |
ROE | 16.90 | 21.20 | 33.23 |
ROCE | 19.37 | 22.01 | 29.69 |
Total Debt To Total Equity | 0.7 | 0.9 | 1.0 |
EBIDTA | 18.47% | 19.73% | 22.71% |
Cash From Operating | 1,097 | 747 | 768 |
Cash From Investing | -713 | -468 | -789 |
Cash From Finance | -164 | -145 | -152 |
Net Cash Flow | 221 | 134 | -172 |
Promoter's Holding
Total Share Capital
-
Offered to Public
-
Promoter’s Holding(Pre-Issue)
98.90%
Promoter’s Holding(Post-Issue)
-
The following points should be kept in mind:
Emcure Pharma IPO is a main-board IPO of 19,365,346 equity shares of a face value of ₹10, aggregating up to ₹1,952.03 Crores. The issue is priced at ₹960 to ₹1008 per share. The minimum order quantity is 14 Shares.
The IPO opens on July 3, 2024, and closes on July 5, 2024.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Emcure Pharma IPO listing date is not yet announced. The tentative date of Emcure Pharma IPO listing is Wednesday, July 10, 2024.
Emcure Pharma IPO lot size is 14 Shares, and the minimum amount required is ₹14,112.
The finalization of Basis of Allotment for Emcure Pharma IPO will be done on Monday, July 8, 2024, and the allotted shares will be credited to your demat account by Tuesday, July 9, 2024
Stock of the Month Announced!
Grab this investment opportunity today!